BidaskClub lowered shares of Viking Therapeutics (NASDAQ:VKTX) from a sell rating to a strong sell rating in a report published on Tuesday morning, BidAskClub reports.
Other analysts have also issued research reports about the company. HC Wainwright reaffirmed a buy rating and set a $31.00 price objective on shares of Viking Therapeutics in a research note on Thursday, April 11th. Maxim Group decreased their price objective on Viking Therapeutics from $28.00 to $20.00 and set a buy rating on the stock in a research note on Thursday, March 14th. Leerink Swann started coverage on Viking Therapeutics in a research note on Friday, February 22nd. They set a market perform rating and a $10.00 price objective on the stock. Svb Leerink started coverage on Viking Therapeutics in a research note on Friday, February 22nd. They set a mkt perform rating on the stock. Finally, William Blair reaffirmed an outperform rating on shares of Viking Therapeutics in a research note on Thursday, March 14th. One equities research analyst has rated the stock with a sell rating, nine have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The company has an average rating of Buy and a consensus target price of $22.54.
Shares of VKTX stock opened at $9.14 on Tuesday. Viking Therapeutics has a fifty-two week low of $3.69 and a fifty-two week high of $24.00. The firm has a market capitalization of $636.72 million, a PE ratio of -22.85 and a beta of 2.75.
Viking Therapeutics (NASDAQ:VKTX) last posted its quarterly earnings data on Wednesday, March 13th. The biotechnology company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.03. As a group, sell-side analysts forecast that Viking Therapeutics will post -0.45 EPS for the current year.
Large investors have recently modified their holdings of the business. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Viking Therapeutics in the 4th quarter worth about $30,000. Lindbrook Capital LLC acquired a new stake in Viking Therapeutics in the 4th quarter worth about $36,000. Great West Life Assurance Co. Can acquired a new stake in Viking Therapeutics in the 4th quarter worth about $53,000. Meeder Asset Management Inc. boosted its stake in Viking Therapeutics by 63.5% in the 4th quarter. Meeder Asset Management Inc. now owns 7,309 shares of the biotechnology company’s stock worth $56,000 after buying an additional 2,839 shares during the last quarter. Finally, Nisa Investment Advisors LLC acquired a new stake in Viking Therapeutics in the 4th quarter worth about $60,000. 65.35% of the stock is currently owned by hedge funds and other institutional investors.
Viking Therapeutics Company Profile
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase II clinical trials to treat patients with non-alcoholic fatty liver disease and elevated low-density lipoprotein cholesterol.
Read More: What is a support level?
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.